Nucana Stock News

Analysts expect that NuCana plc (NASDAQ:NCNA) will post ($0.25) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for NuCanas earnings, with estimates ranging from ($0.29) to ($0.17). NuCana reported earnings per share of ($0.32) during the same quarter last year, which suggests a positive year over []

Goldman Sachs Group Inc. bought a new position in shares of NuCana plc (NASDAQ:NCNA) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 39,332 shares of the companys stock, valued at approximately $109,000. Goldman Sachs Group Inc. owned 0.08% of NuCana at the end [] The post 39,332 Shares in NuCana plc (NASDAQ:NCNA) Acquired by Goldman Sachs Group Inc. appeared first on ETF Daily News .

NuCana: Preparing For A Critical 2022

NuCana plc (NASDAQ:NCNA) has a beta value of 0.73 and has seen 0.73 million shares traded in the recent trading session. The company, currently valued at $140.64M, closed the recent trade at $2.75 per share which meant it lost -$0.04 on the day or -1.56% during that session. The NCNA stock price is -184.73% off Here Is A Bargain Stock You Should Look At : NuCana plc (NCNA) Read More »

Brokerages predict that NuCana plc (NASDAQ:NCNA) will announce ($0.25) earnings per share for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for NuCanas earnings. The highest EPS estimate is ($0.17) and the lowest is ($0.29). NuCana reported earnings of ($0.32) per share in the same quarter last year, which indicates a []

During the last session, NuCana plc (NASDAQ:NCNA)s traded shares were 0.36 million, with the beta value of the company hitting 0.73. At the end of the trading day, the stocks price was $2.84, reflecting an intraday gain of 7.98% or $0.21. The 52-week high for the NCNA share is $7.83, that puts it down -175.7 Does NuCana plc (NASDAQ: NCNA) Still Look Attractive After A 5.58% Selloff Last Week? Read More »

NuCana plc (NASDAQ:NCNA) Investment analysts at Oppenheimer upped their FY2024 earnings per share (EPS) estimates for shares of NuCana in a report issued on Tuesday, November 23rd. Oppenheimer analyst L. Gershell now expects that the company will post earnings of $0.08 per share for the year, up from their prior estimate of $0.04. Several []

NuCana plc (NASDAQ:NCNA) Equities research analysts at Truist Securiti upped their FY2021 earnings per share (EPS) estimates for NuCana in a research report issued to clients and investors on Monday, November 22nd. Truist Securiti analyst R. Karnauskas now forecasts that the company will post earnings per share of ($1.11) for the year, up from []

Enrolled Required Number of Patients to Conduct First Interim Analysis in Phase 3 Biliary Tract Cancer Study in the First Half of 2022

The stock price of NuCana PLC (NASDAQ: NCNA) increased by over 20% during intraday trading today. This is why it happened.

The FDA has granted Fast Track designation to NuCana plc's (NASDAQ: NCNA) Acelarin (NUC-1031) for the first-line treatment of patients with advanced biliary tract cancer. The Company recently anno

EDINBURGH, United Kingdom, Sept. 29, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Acelarin (NUC-1

NUC-3373 Continues to Demonstrate Encouraging Efficacy Signals and a Favorable Safety Profile in Patients with Advanced Colorectal Cancer

NuCana: The Market Continues To Overlook Its ProTide Platform Technology

The risk in these inexpensive bargain stocks is offset by their upside for investors looking for a little more spice in their portfolio. The post 7 Bargain Stocks to Buy Under $5 With the Right Cataly